Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons

Journal of Neurochemistry

Volumn 126, Issue 5, 2013, Pages 685-695

  Cho, Du Hyong ^a   Lee, Eun Joo ^a   Kwon, Kyoung Ja ^a   Shin, Chan Young ^a   Song, Kee Ho ^a   Park, Jung Hyun ^b   Jo, Inho ^b   Han, Seol Heui ^a  

^a Konkuk University School of Medicine   (South Korea)

^b Ewha Womans University School of Medicine   (South Korea)

Author keywords

cyclin dependent kinase 5; p35; phosphorylation; proteasomal degradation; tau; troglitazone

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; LACTACYSTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN P53; ROSIGLITAZONE; SERINE; TAU PROTEIN; THREONINE; TROGLITAZONE;

ANIMAL CELL; ARTICLE; BRAIN CELL; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; EMBRYO; ENZYME ACTIVITY; FEMALE; GENE REPRESSION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

CYCLIN-DEPENDENT KINASE 5; P35; PHOSPHORYLATION; PROTEASOMAL DEGRADATION; TAU; TROGLITAZONE;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; CEREBRAL CORTEX; CHROMANS; CYCLIN-DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3; IMMUNOPRECIPITATION; NEURONS; PHOSPHORYLATION; PPAR GAMMA; PROTEIN PHOSPHATASE 2; RATS; RATS, SPRAGUE-DAWLEY; TAU PROTEINS; THIAZOLIDINEDIONES; TRANSFECTION;

EID: 84883192412     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12264     Document Type: Article

References (51)

1. d'Abramo C., Ricciarelli R., Pronzato M. A., and, Davies P., (2006) Troglitazone, a peroxisome proliferator-activated receptor-gamma agonist, decreases tau phosphorylation in CHOtau4R cells. J. Neurochem. 98, 1068-1077.
2. Alonso Adel C., Mederlyova A., Novak M., Grundke-Iqbal I., and, Iqbal K., (2004) Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J. Biol. Chem. 279, 34873-34881.
3. Augustinack J. C., Schneider A., Mandelkow E. M., and, Hyman B. T., (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 103, 26-35.
4. Blanquicett C., Roman J., and, Hart C. M., (2008) Thiazolidinediones as anti-cancer agents. Cancer Ther. 6, 25-34.
5. Camins A., Verdaguer E., Folch J., Canudas A. M., and, Pallas M., (2006) The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect. 19, 453-460.
6. Cho D. H., Choi Y. J., Jo S. A., Ryou J., Kim J. Y., Chung J., and, Jo I., (2006) Troglitazone acutely inhibits protein synthesis in endothelial cells via a novel mechanism involving protein phosphatase 2A-dependent p70 S6 kinase inhibition. Am. J. Physiol. Cell Physiol. 291, C317-C326.
7. Cho D. H., Seo J., Park J. H., Jo C., Choi Y. J., Soh J. W., and, Jo I., (2010) Cyclin-dependent kinase 5 phosphorylates endothelial nitric oxide synthase at serine 116. Hypertension 55, 345-352.
8. Crews L., Patrick C., Adame A., Rockenstein E., and, Masliah E., (2011) Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer's disease. Cell Death Dis. 2, e120.
9. De Felice F. G., Vieira M. N., Bomfim T. R., et al,. (2009) Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc. Natl Acad. Sci. USA 106, 1971-1976.
10. Derosa G., and, Maffioli P., (2012) Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists on glycemic control, lipid profile and cardiovascular risk. Curr. Mol. Pharmacol. 5, 272-281.
11. Escribano L., Simon A. M., Gimeno E., et al,. (2010) Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 35, 1593-1604.
12. Feinstein D. L., Spagnolo A., Akar C., Weinberg G., Murphy P., Gavrilyuk V., and, Dello Russo C., (2005) Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem. Pharmacol. 70, 177-188.
13. Flaquer M., Lloberas N., Franquesa M., Torras J., Vidal A., Rosa J. L., Herrero-Fresneda I., Grinyo J. M., and, Cruzado J. M., (2010) The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats. Life Sci. 87, 147-153.
14. Galli A., Mello T., Ceni E., Surrenti E., and, Surrenti C., (2006) The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opin. Investig. Drugs 15, 1039-1049.
15. Gong C. X., and, Iqbal K., (2008) Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr. Med. Chem. 15, 2321-2328.
16. Gong C. X., Liu F., Grundke-Iqbal I., and, Iqbal K., (2005) Post-translational modifications of tau protein in Alzheimer's disease. J. Neural. Transm. 112, 813-838.
17. Goodyear S., and, Sharma M. C., (2007) Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5. Exp. Mol. Pathol. 82, 25-32.
18. Hanger D. P., Betts J. C., Loviny T. L., Blackstock W. P., and, Anderton B. H., (1998) New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J. Neurochem. 71, 2465-2476.
19. Hanger D. P., Anderton B. H., and, Noble W., (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 15, 112-119.
20. Hauner H., (2002) The mode of action of thiazolidinediones. Diabetes Metab. Res. Rev. 18 (Suppl 2), S10-S15.
21. Hernandez F., Perez M., de Barreda E. G., Goni-Oliver P., and, Avila J., (2008) Tau as a molecular marker of development, aging and neurodegenerative disorders. Curr. Aging Sci. 1, 56-61.
22. Iqbal K., Liu F., Gong C. X., and, Grundke-Iqbal I., (2010) Tau in Alzheimer disease and related tauopathies. Curr. Alzheimer Res. 7, 656-664.
23. Janson J., Laedtke T., Parisi J. E., O'Brien P., Petersen R. C., and, Butler P. C., (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53, 474-481.
24. Jessberger S., Gage F. H., Eisch A. J., and, Lagace D. C., (2009) Making a neuron: Cdk5 in embryonic and adult neurogenesis. Trends Neurosci. 32, 575-582.
25. Krystof V., and, Uldrijan S., (2010) Cyclin-dependent kinase inhibitors as anticancer drugs. Curr. Drug Targets 11, 291-302.
26. Kwon K. J., Kim J. N., Kim M. K., Lee J., Ignarro L. J., Kim H. J., Shin C. Y., and, Han S. H., (2011) Melatonin synergistically increases resveratrol-induced heme oxygenase-1 expression through the inhibition of ubiquitin-dependent proteasome pathway: a possible role in neuroprotection. J. Pineal Res. 50, 110-123.
27. Lalioti V., Pulido D., and, Sandoval I. V., (2010) Cdk5, the multifunctional surveyor. Cell Cycle 9, 284-311.
28. Landreth G., Jiang Q., Mandrekar S., and, Heneka M., (2008) PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 5, 481-489.
29. Lee M. S., and, Tsai L. H., (2003) Cdk5: one of the links between senile plaques and neurofibrillary tangles? J. Alzheimers Dis. 5, 127-137.
30. Lee V. M., Goedert M., and, Trojanowski J. Q., (2001) Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121-1159.
31. Lovestone S., and, Reynolds C. H., (1997) The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78, 309-324.
32. Lucas J. J., Hernandez F., Gomez-Ramos P., Moran M. A., Hen R., and, Avila J., (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20, 27-39.
33. Luna-Munoz J., Garcia-Sierra F., Falcon V., Menendez I., Chavez-Macias L., and, Mena R., (2005) Regional conformational change involving phosphorylation of tau protein at the Thr231, precedes the structural change detected by Alz-50 antibody in Alzheimer's disease. J. Alzheimers Dis. 8, 29-41.
34. Maeshiba Y., Kiyota Y., Yamashita K., Yoshimura Y., Motohashi M., and, Tanayama S., (1997) Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 47, 29-35.
35. Noble W., Olm V., Takata K., et al,. (2003) Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38, 555-565.
36. Ondrey F., (2009) Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin. Cancer Res. 15, 2-8.
37. O'Reilly J. A., and, Lynch M., (2012) Rosiglitazone improves spatial memory and decreases insoluble Abeta(1-42) in APP/PS1 mice. J. Neuroimmune Pharmacol. 7, 140-144.
38. Patrick G. N., Zhou P., Kwon Y. T., Howley P. M., and, Tsai L. H., (1998) p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway. J. Biol. Chem. 273, 24057-24064.
39. Pedersen W. A., McMillan P. J., Kulstad J. J., Leverenz J. B., Craft S., and, Haynatzki G. R., (2006) Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp. Neurol. 199, 265-273.
40. Schwartz S., Raskin P., Fonseca V., and, Graveline J. F., (1998) Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N. Engl. J. Med. 338, 861-866.
41. Searcy J. L., Phelps J. T., Pancani T., et al,. (2012) Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease. J. Alzheimers Dis. 30, 943-961.
42. Sengupta A., Kabat J., Novak M., Wu Q., Grundke-Iqbal I., and, Iqbal K., (1998) Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch. Biochem. Biophys. 357, 299-309.
43. Sengupta A., Grundke-Iqbal I., and, Iqbal K., (2006) Regulation of phosphorylation of tau by protein kinases in rat brain. Neurochem. Res. 31, 1473-1480.
44. Su S. C., and, Tsai L. H., (2011) Cyclin-dependent kinases in brain development and disease. Annu. Rev. Cell Dev. Biol. 27, 465-491.
45. Takashima A., (2010) Tau aggregation is a therapeutic target for Alzheimer's disease. Curr. Alzheimer Res. 7, 665-669.
46. To A. W., Ribe E. M., Chuang T. T., Schroeder J. E., and, Lovestone S., (2011) The epsilon3 and epsilon4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice. PLoS ONE 6, e16991.
47. Wei S., Yang H. C., Chuang H. C., Yang J., Kulp S. K., Lu P. J., Lai M. D., and, Chen C. S., (2008) A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells. J. Biol. Chem. 283, 26759-26770.
48. Yoon S. Y., Park J. S., Choi J. E., Choi J. M., Lee W. J., Kim S. W., and, Kim D. H., (2010) Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells. Neurobiol. Dis. 40, 449-455.
49. Zhao W. Q., and, Townsend M., (2009) Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim. Biophys. Acta 1792, 482-496.
50. Zhu G., Fujii K., Belkina N., Liu Y., James M., Herrero J., and, Shaw S., (2005) Exceptional disfavor for proline at the P + 1 position among AGC and CAMK kinases establishes reciprocal specificity between them and the proline-directed kinases. J. Biol. Chem. 280, 10743-10748.
51. Zukerberg L. R., Patrick G. N., Nikolic M., et al,. (2000) Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth. Neuron 26, 633-646.